Short answer
Erasca, Inc. (ERAS) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 8.01 (Other Events). ERAS-0015 Phase 1 monotherapy data now expected by mid-May 2026, narrowing prior guidance of first half 2026.
Erasca, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- ERAS-0015 Phase 1 monotherapy data now expected by mid-May 2026, narrowing prior guidance of first half 2026
- Readout combines AURORAS-1 and JYP0015M101 trials evaluating pan-RAS molecular glue in RAS-mutant solid tumors
- AURORAS-1 covers RAS-mutant solid tumors; Joyo-led JYP0015M101 evaluates specific RAS mutations in China
- Near-term data catalyst could clarify ERAS-0015’s clinical activity and support or weaken the program’s development case
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Erasca, Inc. 8-K filings
Get the next ERAS 8-K as it lands
Follow ERAS for push alerts, or ask the research agent what this filing means.